Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 9CNS 5Genitourinary 4Gastrointestinal 4Thoracic 2Gynecologic 2Breast 2Other solid neoplasm 1NET 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Colonic Neoplasms 3Colorectal Neoplasms 2Neoplasms 1Liver Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Oxaliplatin 1409Fluorouracil 1298Capecitabine 1085Gemcitabine 1042Leucovorin 928Irinotecan 815Bevacizumab 803Cisplatin 666Radiotherapy 535Cetuximab 469pembrolizumab 428Paclitaxel 389Nivolumab 336130-nm albumin-bound paclitaxel 322Drug Therapy 314Docetaxel 286S 1 (combination) 273Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 209Surgical Procedures, Operative 203tislelizumab 202Radiosurgery 202lenvatinib 201apatinib 198Carboplatin 186Magnetic Resonance Spectroscopy 181regorafenib 180

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × epothilone B × Gastrointestinal × Clear all
NCT00969046 2020-12-08

Dose-Escalation Study in Advanced Colon Cancer Patients

Novartis

Phase 1 Completed
60 enrolled
Gastrointestinal

Colonic Neoplasms

NCT00159484 2017-06-27

Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer

University of Southern California

Phase 1/2 Unknown
75 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT00273312 2017-02-07

Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma

Novartis

Phase 2 Completed
25 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00035087 2013-12-04

EPO906 Therapy in Patients With Advanced Colorectal Cancer

Novartis

Phase 2 Completed
62 enrolled
Gastrointestinal

Carcinoma, Colonic Neoplasms, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡